Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $17

Benzinga · 2d ago
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $20 to $17.